Cytovance Biologics Expands GMP Warehouse and Manufacturing Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cytovance Biologics Expands GMP Warehouse and Manufacturing Operations



Cytovance Biologics, a full-service contract manufacturer of mammalian and microbial biologics, continues to work on the expansion of a manufacturing operations and GMP warehousing facility. The multi-million dollar capital investment project is expected to be completed by June 2014.
 
Cytovance selected a construction site two miles north of its current campus in Oklahoma.  The new facility, located at 3500 N. Santa Fe, will house 20,000 ft2 of climate controlled and monitored GMP warehouse space and 10,000 ft2 of space for existing and future manufacturing operations. Initially, this cleanroom space will be used for weighing and dispensing activities.
 
“Our new GMP warehouse will support incoming and outgoing supply-chain activities and provide full segregation between incoming, quarantine, and released materials,” explained Don Wuchterl, senior vice-president of manufacturing operations in a press release.

Source: Cytovance Biologics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here